Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.44 |
| ▸ | JAK2 | O60674 | 3/20 | 0.40 |
| ▸ | DHFR | P00374 | 2/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 2/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23828413 | 0.86 | ALDH1A1 (0.40) | ATRPIK3CAHDAC6 | |
| SCHEMBL23828502 | 0.80 | NPC1 (0.48) | PIK3CG | |
| SCHEMBL23828386 | 0.79 | PTGS2 (0.46) | PTGS2JAK2ATRJAK3PTK2 | |
| SCHEMBL30507590 | 0.78 | PTGS2 (0.46) | PTGS2JAK2JAK3PTK2PTGS1 | |
| SCHEMBL23828576 | 0.78 | HPGD (0.52) | PTGS2PTGS1 | |
| SCHEMBL23828557 | 0.78 | AOC3 (0.47) | PTGS2JAK2ATRJAK3PTK2 | |
| SCHEMBL25330071 | 0.77 | PTGS2 (0.40) | PTGS2JAK2DHFRATRJAK3 | |
| SCHEMBL23828609 | 0.75 | PIK3CG (0.36) | PTGS2PIK3CGPTGS1 | |
| SCHEMBL23828457 | 0.74 | TYK2 (0.41) | PTGS2 | |
| SCHEMBL23828565 | 0.71 | KDM4E (0.46) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264161-B2 | Heterocyclic adenosine receptor antagonists | EXELIXIS, INC. (US) | 2025-04-01 | — | — | US | claimed |
| US-20230382917-A1 | Heterocyclic Adenosine Receptor Antagonists | EXELIXIS, INC. | 2023-11-30 | — | — | US | claimed |
| US-11718622-B2 | Heterocyclic adenosine receptor antagonists | EXELIXIS INC. (US) | 2023-08-08 | — | — | US | claimed |
| US-12264161-B2 | Heterocyclic adenosine receptor antagonists | EXELIXIS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20230382917-A1 | Heterocyclic Adenosine Receptor Antagonists | EXELIXIS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382917-A1 | Heterocyclic Adenosine Receptor Antagonists | EXELIXIS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382917-A1 | Heterocyclic Adenosine Receptor Antagonists | EXELIXIS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-11718622-B2 | Heterocyclic adenosine receptor antagonists | EXELIXIS INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718622-B2 | Heterocyclic adenosine receptor antagonists | EXELIXIS INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718622-B2 | Heterocyclic adenosine receptor antagonists | EXELIXIS INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20210292332-A1 | Heterocyclic Adenosine Receptor Antagonists | EXELIXIS, INC. | 2021-09-23 | — | — | US | disclosed |
| US-20210292332-A1 | Heterocyclic Adenosine Receptor Antagonists | EXELIXIS, INC. | 2021-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292332-A1 | Heterocyclic Adenosine Receptor Antagonists | ADORA2A, ADORA1, ADORA3 | PTGS2 830/4885JAK2 1948/4885DHFR 514/4885 |
| US-20230382917-A1 | Heterocyclic Adenosine Receptor Antagonists | ADORA2A, ADORA1, ADORA3 | PTGS2 830/4885JAK2 1948/4885DHFR 514/4885 |
| US-11718622-B2 | Heterocyclic adenosine receptor antagonists | ADORA2A, ADORA1, ADORA3 | PTGS2 830/4885JAK2 1948/4885DHFR 514/4885 |
| US-12264161-B2 | Heterocyclic adenosine receptor antagonists | ADORA2A, ADORA1, ADORA3 | PTGS2 830/4885JAK2 1948/4885DHFR 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.